Neurocrine Biosciences, Inc.
NBIX
$155.80
$5.213.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 42.25% | 28.33% | 27.78% | 16.49% | 11.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.25% | 28.33% | 27.78% | 16.49% | 11.12% |
| Cost of Revenue | 13.80% | 41.51% | 30.05% | 27.61% | 63.21% |
| Gross Profit | 68.05% | 22.39% | 26.68% | 10.77% | -13.83% |
| SG&A Expenses | 15.19% | 5.11% | 24.46% | 25.57% | 13.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.50% | 19.81% | 27.05% | 26.52% | 33.88% |
| Operating Income | 684.81% | 56.69% | 29.49% | -10.07% | -77.49% |
| Income Before Tax | 1,578.91% | 47.23% | 53.34% | 61.76% | -57.39% |
| Income Tax Expenses | 619.12% | 44.03% | 36.03% | 54.76% | 176.40% |
| Earnings from Continuing Operations | 2,405.06% | 49.08% | 61.40% | 65.38% | -81.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,405.06% | 49.08% | 61.40% | 65.38% | -81.80% |
| EBIT | 684.81% | 56.69% | 29.49% | -10.07% | -77.49% |
| EBITDA | 517.57% | 54.31% | 29.12% | -9.63% | -71.93% |
| EPS Basic | 2,386.36% | 49.22% | 64.16% | 68.41% | -81.79% |
| Normalized Basic EPS | 367.85% | 51.19% | 27.74% | -8.38% | -64.38% |
| EPS Diluted | 2,311.62% | 47.67% | 64.52% | 68.25% | -81.14% |
| Normalized Diluted EPS | 367.52% | 49.87% | 27.81% | -7.43% | -64.04% |
| Average Basic Shares Outstanding | 0.80% | -0.10% | -1.68% | -1.79% | -0.10% |
| Average Diluted Shares Outstanding | 0.88% | 0.78% | -1.73% | -2.79% | -1.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |